Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Porphyric neuropathy.

James W Albers1, John K Fink

  • 1Department of Neurology, 1C325/0032 University Hospital, University of Michigan Health System, 1500 East Medical Center Drive, Ann Arbor 48109-0032, USA. jwalbers@umich.edu

Muscle & Nerve
|September 17, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward therapeutic trials in primary lateral sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2025
Same author

Nonglycemic and Glycemic Risk Factors for Painful Neuropathic Symptoms and for Distal Symmetrical Polyneuropathy (DSPN) in the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.

Diabetes care·2025
Same author

Primary Lateral Sclerosis (Progressive Spinobulbar Spasticity): Serial Analysis Over Many Years Increases Diagnostic Certainty.

Neurology·2025
Same author

The Spastic Paraplegia-Centers of Excellence Research Network (SP-CERN): Clinical Trial Readiness for Hereditary Spastic Paraplegia.

Neurology. Genetics·2025
Same author

Neuropathic Pain With and Without Diabetic Peripheral Neuropathy in Type 1 Diabetes.

Diabetes care·2024
Same author

The hereditary spastic paraplegias.

Handbook of clinical neurology·2023
Same journal

Join AANEM.

Muscle & nerve·2026
Same journal

Targeted Muscle Reinnervation for Management and Prevention of Symptomatic Neuroma.

Muscle & nerve·2026
Same journal

AANEM News & Insights.

Muscle & nerve·2026
Same journal

Fat-Fraction Quantification Using Three-Point Dixon Technique in Duchenne Muscular Dystrophy and Its Correlation With Clinical Progression and Genotypic Characteristics: A Single Centre One-Year Prospective Study.

Muscle & nerve·2026
Same journal

Characterizing Combined Central and Peripheral Demyelination-Insights From a Multimodal Comparison With Chronic Inflammatory Demyelinating Polyneuropathy and Multiple Sclerosis.

Muscle & nerve·2026
Same journal

Electrical Modalities in the Rehabilitation of Peripheral Nerve Injuries: State of the Literature and Current Clinical Applications.

Muscle & nerve·2026
See all related articles

Hepatic porphyrias are rare genetic disorders affecting heme biosynthesis, often causing severe neuropathy. Early diagnosis is crucial as symptoms mimic Guillain-Barré syndrome but have distinct features.

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Hepatic porphyrias are rare, autosomal-dominant metabolic disorders impacting heme biosynthesis.
  • These conditions involve enzymatic defects in porphyrin metabolism, leading to the accumulation of toxic intermediates.
  • Heme, a crucial metalloporphyrin, is central to the metabolic pathway affected.

Observation:

  • Porphyric neuropathy presents with symptoms, signs, and CSF abnormalities that can be mistaken for Guillain-Barré syndrome.
  • Key differentiating features include psychological disturbances, proximal asymmetric weakness, and specific electrodiagnostic findings.
  • Patients with porphyria are often misdiagnosed or experience diagnostic delays.

Findings:

  • The neuropathy in hepatic porphyrias can be severe and is linked to elevated delta-aminolevulinic acid levels.

Related Experiment Videos

  • Distinct clinical and electrodiagnostic features differentiate porphyric neuropathy from other neuropathies.
  • Laboratory confirmation is essential for accurate diagnosis.

    • Implications:

    • Early identification of porphyric neuropathy is vital due to its severity and potential for treatment.
    • Understanding the neurotoxic mechanisms, possibly involving delta-aminolevulinic acid, is key for developing targeted therapies.
    • Distinguishing porphyric neuropathy from Guillain-Barré syndrome improves patient outcomes through appropriate management and avoidance of provocative agents.